Solana Company Q4 FY2022 Earnings Call

· Earnings call transcript and AI-powered summary

Key Highlights
  • Product Focus: Continued emphasis on U.S. and Canadian commercialization of the Portable Neuromodulation Stimulator (PoNS) device, used to treat gait and balance deficits in patients with multiple sclerosis (MS), traumatic brain injury (TBI), and, newly in Canada, stroke.
  • Regulatory Progress: Health Canada approved PoNS for stroke-related gait deficits. In the U.S., the device has FDA breakthrough designations for both MS and stroke.
  • Training and Accessibility:
    • Online training module for physical therapists has replaced longer, in-person courses—training now possible in under 3 hours.
    • New partnership with telehealth leader UpScript enables remote prescription/evaluation and home delivery via ponstherapy.com.
  • Discounted Access Program: The Patient Therapy Access Program (PTAP)—offering devices at an 85% discount ($3,895 vs. list price $14,500)—has been extended through June 2023.
  • Clinical and Real-World Data Initiatives:
    • PoNSTEP observational trial added new academic partners for real-world usage data.
    • Registry and real-world evidence collection ongoing for future reimbursement initiatives.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good day, and thank you for standing by. Welcome to the Helius Medical Technologies Fourth Quarter and Year-End 2022 Earnings Conference Call. [Operator Instructions] As a reminder, today's conference may be recorded. I'd now like to hand the call over to your speaker, Michelle Bilski, Investor Relations. Please go ahead. Michelle Bilski: Thank you, operator. Welcome to the fourth quarter and year-end 2022 Earnings Conference Call for Helius Medical Technologies. This is Michelle Bilski of In-Site Communications, Investor Relations for Helius. With me on today's call are Dane Andreeff, Helius Medical's President and Chief Executive Officer; and Jeff Mathiesen, Chief Financial Officer. Also on the call today is Dr. Antonella Favit-Van Pelt, Helius Medical's Chief Medical Officer, who will be available as needed during Q&A. At this time, all participants have been placed in a listen-only mode. Please note that this call is being recorded, and access to the webcast can be obtained through the Investors section of Helius website at www.heliusmedical.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our most recent

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional